ATNM Actinium Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ATNM

Price (delayed)

$0.9639

Market cap

$30.31M

P/E Ratio

2.68

Dividend/share

N/A

EPS

$0.36

Enterprise value

-$4.83M

?
Relative Growth: Rel. Growth: 31
Relative Strength: Rel. Strength: 11
Relative Valuation: Rel. Valuation: 92
Relative Profitability: Rel. Profitability: 88

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic ...

Highlights
ATNM's net income has surged by 148% since the previous quarter and by 128% year-on-year
The EPS has soared by 148% from the previous quarter and by 127% YoY
The debt has decreased by 12% from the previous quarter but it has increased by 4% YoY
The quick ratio has decreased by 45% YoY and by 31% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.actiniumpharma.com
Peers: KMDA BMRN

Key stats

What are the main financial stats of ATNM

ATNM stock price

How has the Actinium Pharmaceuticals stock price performed over time
Intraday
17.39%
1 week
22.48%
1 month
6.51%
1 year
-39.76%
YTD
-29.13%
QTD
-1.64%

Financial performance

How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$35.09M
Gross profit
$35.09M
Operating income
$9.56M
Net income
$11.31M
Gross margin
100%
Net margin
32.2%
ATNM's net income has surged by 148% since the previous quarter and by 128% year-on-year
The operating income has surged by 137% since the previous quarter and by 122% year-on-year
The net margin has soared by 100% from the previous quarter
Actinium Pharmaceuticals's operating margin has soared by 100% from the previous quarter

Price vs fundamentals

How does ATNM's price correlate with its fundamentals

Growth

What is Actinium Pharmaceuticals's growth rate over time

Valuation

What is Actinium Pharmaceuticals stock price valuation
P/E
2.68
P/B
1
P/S
0.86
EV/EBIT
-0.43
EV/EBITDA
-0.4
EV/Sales
-0.14
The EPS has soared by 148% from the previous quarter and by 127% YoY
The price to book (P/B) is 83% lower than the last 4 quarters average of 5.9 and 71% lower than the 5-year quarterly average of 3.5
The equity has surged by 59% year-on-year
ATNM's price to sales (P/S) is 100% less than its 5-year quarterly average of 1068.9 and 100% less than its last 4 quarters average of 343.1

Efficiency

How efficient is Actinium Pharmaceuticals business performance
ATNM's return on equity has surged by 159% year-on-year and by 138% since the previous quarter
The company's return on assets has surged by 154% QoQ and by 141% YoY
The ROS has soared by 100% from the previous quarter

Dividends

What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNM.

Financial health

How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total liabilities has plunged by 78% YoY and by 77% from the previous quarter
The quick ratio has decreased by 45% YoY and by 31% from the previous quarter
The debt is 96% less than the equity
The company's debt to equity has shrunk by 94% QoQ and by 43% YoY
The equity has surged by 59% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.